OBJECTIVE: To probe into the effects of dapagliflozin combined with liraglutide on inflammatory factors

glucolipid metabolism and liver function in patients with type 2 diabetes（T2 DM） combined with non-alcoholic fatty liver disease（NAFLD）. METHODS: A total of 135 patients with T2 DM complicated with NAFLD admitted into the endocrinology department of the hospital from Mar. 2020 to May 2021 were extracted to be divided into the dapagliflozin group

liraglutide group and combination group

with 45 cases in each group using SAS statistical software. On the basis of life intervention

patients in the dapagliflozin group

liraglutide group and combination group were treated with dapagliflozin

liraglutide and dapagliflozin combined with liraglutide

respectively. Serum inflammatory indicators such as high sensitivity C-reactive protein（hs-CRP） and soluble interleukin-2 receptor（SIL-2 R）

glucose and lipid metabolism indicators such as glycated hemoglobin（HbA

1

c） and triacylglycerol glucose index（TyG）

and liver function indicators such as alanine aminotransferase（ALT） and bile acid（TBA）

liver physical indicators such as fatty liver index（FLI） and liver hardness（LSM） before and after treatment

and adverse drug reactions of three groups were observed. RESULTS: After treatment of 20 weeks

the levels of hs-CRP and SIL-2 R in three groups were significantly lower than those before treatment

and the combination group was significantly lower than the dapagliflozin group and liraglutide group

the differences were statistically significant（P

<

0.05）. The levels of HbA

1

c and TyG in three groups were significantly lower than those before treatment

and the combination group was significantly lower than the dapagliflozin group and liraglutide group

the differences were statistically significant（P

<

0.05）. The levels of ALT and TBA in three groups were significantly lower than those before treatment

the differences were statistically significant（P

<

0.05）

yet there was no significant difference among three groups（P

>

0.05）. The levels of FLI and LSM in three groups were significantly lower than those before treatment

and the combination group was significantly lower than the dapagliflozin group and liraglutide group

the differences were statistically significant（P

<

0.05）. The incidence of adverse drug reactions in the dapagliflozin group

liraglutide group and combination group were 6.67%（3/45）

8.89%（4/45） and 11.11%（5/45）

the difference was not statistically significant（P

>

0.05）. CONCLUSIONS: Dapagliflozin and liraglutide can effectively reduce the level of inflammation in patients with T2 DM complicated with NAFLD

improve the disorder of glucolipid metabolism

and promote the recovery of fatty liver

and the combination of the drugs is more effective.